Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Biotechnology

Healthcare
$9.24 -3.20%

-$0.39 today

Market cap
$326.66M
Beta
0.89
P/E (TTM)
-7.5
EPS (TTM)
-$1.57
52W Low $3.69High $16.33

Volume 0.20M

Average 0.26M

CTNM EBITDA Margin

EBITDA as a percentage of revenue.

Contineum Therapeutics, Inc. Class A Common StockNASDAQ: CTNM

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2023
47.1%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CTNM compares with its peers on the latest reported figures

CTNM Competitors Peer median
EBITDA Margin for CTNM and competitors
Company Period LTM level YoY 3-year change
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026-590.7% ——
ACIUAC Immune S.A.LTM Mar 2026-1740.8% -1565.2 pp-167.5 pp
CTNMContineum Therapeutics, Inc. Class A Common StockFY2025— ——
LBRXLB Pharmaceuticals Inc Common StockFY2025— ——
GHRSGH Research PLCFY2025— ——
ANROAlto Neuroscience, Inc.FY2025— ——
SPTXSeaport Therapeutics, Inc. Common Stock—— ——
MPLTMapLight Therapeutics, Inc.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding CTNM) -1165.8%-1565.2 pp-167.5 pp

Competitors are the stored peer set for CTNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0050M00
Cost of Revenue000258K0
Gross Profit0050M(258K)0
Gross Margin——100.0%——
Research & Development22.36M16.89M27.6M38.16M51.52M
Selling, General & Admin6.29M5.83M6.32M12.47M16.54M
Operating Expenses28.65M22.72M66.08M50.64M68.06M
Depreciation & Amortization325K329K195K258K323K
EBITDA(28.34M)(23.54M)23.57M(42M)(59.66M)
EBITDA Margin——47.1%——
Operating Income(28.65M)(22.72M)(16.08M)(50.89M)(68.06M)
Operating Margin——-32.2%——
Interest Income77K761K4.61M8.91M8.25M
Interest Expense332K388K208K00
Other Income / Expenses(354K)(1.53M)39.25M8.64M8.08M
Income Before Tax(29M)(24.25M)23.17M(42.26M)(59.98M)
Pre-Tax Margin——46.3%——
Income Tax Expense00450K00
Net Income(29M)(24.25M)22.72M(42.26M)(59.98M)
Net Margin——45.4%——
EPS (Basic)(1.15)(0.97)0.13(1.63)(2.17)
EPS (Diluted)(1.15)(0.97)0.13(1.63)(2.17)
Weighted Avg Shares25.13M25.13M25.13M25.85M27.7M
Weighted Avg Shares (Diluted)25.13M25.13M25.13M25.85M27.7M

Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Intrinsic Alpha fair value

Locked

Current Price

$9.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.